Relavo, based in New York, is a female-founded medical technology company focused on making home dialysis more accessible. Its core product, PeritoneX, is being developed to improve the safety of peritoneal dialysis (PD) for patients. The company is advancing PeritoneX with support from philanthropic investors. Relavo will receive an investment from the National Kidney Foundation's Innovation Fund to further develop the technology. The NKF Innovation Fund is the foundation's philanthropic impact investment program. The article does not disclose financial terms or operating metrics. Relavo develops PeritoneX, an inline connection device intended to internally disinfect dialysis tubing and lower bacterial infection rates associated with home peritoneal dialysis. The company was founded in 2018 by CEO Sarah Lee, CTO Tejasvi Desai and Chief Innovation Officer Anna Bailey. Relavo is in the prototype development phase and plans to submit for FDA clearance in mid-2023, run clinical trials to demonstrate impact on infection rates, and aims for early sales by the end of 2024 assuming regulatory timelines proceed as expected. The team says medtech timelines and limited prior PI/grant experience have made non-dilutive funding and legitimacy important early challenges. In August 2020 Relavo won a $500,000 prize from the Kidney X Innovation accelerator that the coverage highlights as a major boost. The company has also been accepted into the MedTech Innovator Accelerator and MassChallenge Boston programs. Relavo operates out of the Maryland Development Center in downtown Baltimore as it continues product development.

Total raised

$1M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2021